Daniel Y.C. Heng - Concepedia

Author

Daniel Y.C. Heng

Also Known As

Daniel Heng, Daniel Y C Heng, Daniel Y Heng, Daniel Y. C. Heng, Daniel Y. Heng, Daniel Y.C. Heng, Daniel YC Heng, Daniel Y C Heng, Maughan, Benjamin

223

Publications

17.8K

Citations

H-Index

Concepts

All Affiliations

University of Calgary Dana-Farber Cancer Institute Princess Margaret Cancer Centre Aarhus University Hospital Harvard University

About

Daniel Y.C. Heng is an author at University of Calgary specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	53	6.7K
2	Health Sciences	3	3	145
3	Biostatistics	2	2	1K
4	Public Health	1	1	30
5	Cell Biology	1	1	12

Daniel Y.C. Heng

109

Publications

13.8K

Citations

H-Index

Page 1

	Year	Citations
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Journal of Clinical Oncology	2009	2.1K
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Toni K. Choueiri, Bernard Escudier, Thomas Powles, New England Journal of Medicine	2015	1.2K
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, The Lancet Oncology External ValidationUrologyPopulation-based StudyGenitourinary CancerMedicine	2013	1K
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Toni K. Choueiri, Bernard Escudier, Thomas Powles, The Lancet Oncology UrologyGenitourinary CancerKidney ResearchMedicineCabozantinib Versus Everolimus	2016	927
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Journal of Clinical Oncology Tyrosine Kinase InhibitorUrologyOncologyGenitourinary CancerMedicine	2017	502
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini, European Urology UrologySurgical OncologyGenitourinary CancerMedicineCytoreductive Nephrectomy	2014	467
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Jenny J. Ko, Wanling Xie, Nils Kroeger, The Lancet Oncology First-line Targeted TherapyUrologyPopulation-based StudyGenitourinary CancerMedicine	2015	364
The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy Toni K. Choueiri, Wanling Xie, Christian Kollmannsberger, The Journal of Urology	2010	354
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival Shaan Dudani, Guillermo de Velasco, J. Connor Wells, JAMA Network Open	2021	273

Page 1